Nektar Therapeutics Loss on Contract Termination
Nektar Therapeutics (NKTR) reported Loss on Contract Termination of $7.34 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Notes
us-gaap:LossOnContractTermination · last filed 2025-03-14
- Nektar Therapeutics loss on contract termination for the quarter ending 2024-09-30 was $46.00K.
- Nektar Therapeutics loss on contract termination for the quarter ending 2024-06-30 was $4.96M.
- Nektar Therapeutics loss on contract termination for the quarter ending 2024-03-31 was $975.00K, a 6.91% increase year-over-year.
- Nektar Therapeutics loss on contract termination for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics loss on contract termination for fiscal 2024 was $7.34M, a 1.40% decline from fiscal 2023.
- Nektar Therapeutics loss on contract termination for fiscal 2023 was $7.45M, a 31.68% decline from fiscal 2022.
- Nektar Therapeutics loss on contract termination for fiscal 2022 was $10.90M.
| Period end | Loss on Contract Termination 3 month | Loss on Contract Termination 6 month | Loss on Contract Termination 9 month | Loss on Contract Termination 12 month | Loss on Contract Termination 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $7.34M 10-K · filed 2025-03-14 | ||||
| 2024-09-30 | $46.00K 10-Q · filed 2024-11-08 | $5.98M 10-Q · filed 2024-11-08 | |||
| 2024-06-30 | $4.96M 10-Q · filed 2024-08-09 | $5.93M 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | $975.00K 10-Q · filed 2024-05-10 | ||||
| 2023-12-31 | $7.45M 10-K · filed 2025-03-14 | $1.95M 10-K · filed 2024-03-05 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-08 | $912.00K 10-Q · filed 2024-11-08 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 | $912.00K 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $912.00K 10-Q · filed 2024-05-10 | ||||
| 2022-12-31 | $10.90M 10-K · filed 2023-02-28 | ||||
| 2022-09-30 | $5.02M 10-Q · filed 2022-11-04 | $7.06M 10-Q · filed 2022-11-04 | |||
| 2022-06-30 | $566.00K 10-Q · filed 2022-08-05 | $2.04M 10-Q · filed 2022-08-05 | |||
| 2022-03-31 | $1.50M 10-Q · filed 2022-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |